Drug Profile
Research programme: marine microorganism-derived antibacterials - Nereus Pharmaceuticals
Alternative Names: NPI-3114; NPI-3304Latest Information Update: 16 Jan 2014
Price :
$50
*
At a glance
- Originator Nereus Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 11 Jul 2011 Preclinical development is ongoing in USA
- 24 Jan 2006 Preclinical trials in Bacterial infections in USA (unspecified route)